ANRIL by inhibiting the level of adiponectin receptor (AdipoR1), a key regulator of glucose metabolism, thus affected glucose uptake and cell maintenance in AML.20 The gene discussed is CDKN2B-AS1; the disease is acute myeloid leukemia.